ScholarLens Back to search
2015•Anti-infection PharmacyRequires access

Recent Clinical Efficacy of Entecavir in Patients with Chronic Hepatitis B

Wuhan Zhang

Open publisher page 0 citations

Abstract

Objective: To evaluate the recent clinical efficacy of entecavir in patients with chronic hepatitis B(CHB) and to rovide a reference for clinical rational medication. Methods: Sixty-eight patients of CHB were randomly divided into two groups(each group of 34 cases), lamivudine therapy was in group A and entecavir therapy was in group B. Two groups patients were treated after 6 weeks, the situation of ALT, AST, GGTP, GGT and HBV DNA levels were evaluated. The improvement of HBV-DNA overcast rate of the two groups patients after 3 months treatment was analyzed. Results: The ALT, AST, GGT and HBV DNA levels of Group B patients after treatment of 6 weeks were significantly better than those of group A(P<0.05). The HBV- DNA positive rates of Group B patients after treatment of 3months were significantly lower than those of group A(P<0.05). Conclusion: Entecavir can obviously raise the recent clinical efficacy in Patients with Chronic Hepatitis B

About this research paper

What this paper is about

Objective: To evaluate the recent clinical efficacy of entecavir in patients with chronic hepatitis B(CHB) and to rovide a reference for clinical rational medication. Methods: Sixty-eight patients of CHB were randomly divided into two groups(each group of 34 cases), lamivudine therapy was in group A and entecavir therapy was in group B. Two groups patients were treated after 6 weeks, the situation of ALT, AST, GGTP, GGT and HBV DNA levels were evaluated. The improvement of HBV-DNA overcast rate of the two groups patients after 3 months treatment was analyzed. Results: The ALT, AST, GGT and HBV DNA levels of Group B patients after treatment of 6 weeks were significantly better than those of group A(P<0.05). The HBV- DNA positive rates of Group B patients after treatment of 3months were significantly lower than those of group A(P<0.05). Conclusion: Entecavir can obviously raise the recent clinical efficacy in Patients with Chronic Hepatitis B

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective: To evaluate the recent clinical efficacy of entecavir in patients with chronic hepatitis B(CHB) and to rovide a reference for clinical rational medication. Methods: Sixty-eight patients of CHB were randomly divided into two groups(each group of 34 cases), lamivudine therapy was in group A and entecavir therapy was in group B. Two groups patients were treated after 6 weeks, the situation of ALT, AST, GGTP, GGT and HBV DNA levels were evaluated. The improvement of HBV-DNA overcast rate of the two groups patients after 3 months treatment was analyzed. Results: The ALT, AST, GGT and HBV DNA levels of Group B patients after treatment of 6 weeks were significantly better than those of group A(P<0.05). The HBV- DNA positive rates of Group B patients after treatment of 3months were significantly lower than those of group A(P<0.05). Conclusion: Entecavir can obviously raise the recent clinical efficacy in Patients with Chronic Hepatitis B

Key concepts: Entecavir, Lamivudine, Medicine, Internal medicine, Chronic hepatitis, Gastroenterology, Hepatitis B, Clinical efficacy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Recent Clinical Efficacy of Entecavir in Patients with Chronic Hepatitis B — Research Paper | ScholarLens